2020 Healthcare & Pharmaceutical Awards

GHP / 2020 Healthcare & Pharmaceutical Awards 37 , Most Innovative Biotech VC Fund Manager 2020 ORI Capital Limited is unlike anyof its competitorswithin theVentureCapital sector. Employing the ‘Quantamental’ strategyusually seen inhedge funds, thefirmprovides a scientific approach to investment in thehealthcare sector, enabling its portfolio companies tohave access to predominantlyunattainable informationandmake informeddecisions. Thanks toORI’s ground- breakingORIzon system, thefirmis revolutionising the venture capital landscape for the better. ORI Capital Limited is a venture capital firm that was established in 2015 by former Head of Goldman Sachs Healthcare Investment Banking for Greater China, Simone Song. Investing in innovative companies within the healthcare industry around the world, ORI launched the ORI Healthcare Fund, L.P., a healthcare fund at a fund size of US$200 million, in January 2016 in order to be both financially successful as well as having a large and positive social impact. As a venture capital fund manager following a ‘Quantamental’ strategy, ORI combines fundamental research with quantitative analysis throughout the investment process. Whilst this is a common strategy for hedge funds to adopt, it is ground-breaking to see this strategy being used in venture capital or private equity investments. ORIzon, the firm’s proprietary AI enabled research system, has been created with the Quantamental strategy in mind, to create and maintain a watch list for potential investment targets. ORI obtained the Hong Kong SFC asset management (Type 9) license in January 2020, and the patent application for ORIzon is currently underway at the Hong Kong Intellectual Property Department. Focusing on the 10,000 predominantly private healthcare companies engaged in therapeutics, drug delivery and diagnosis of large diseases or diseases with a high mortality rate, ORI has found there to be little to no financial information publicly available. Therefore, utilising the scientific approach of the Quantamental strategy and the extensive network curated by Simone and her team, ORI would be able to overcome the two principal challenges faced in its industry; identifying investment targets and obtaining comparable information to provide a competitive landscape for the firm’s portfolio of companies. ORI would have a wide coverage of relevant companies, profound analysis of the competitive landscape, as well as substantial accessibility so as to approach investment targets. For the ten portfolio companies ORI has invested in so far, ORI would also promote partnership between the highly innovative companies within the ORI portfolio to enable exponential growth. ORI would also enable the firms to realise their China value and help in managing exit processes to maximise their value through Simone’s investment banking experience and connections. In addition to the already unparalleled opportunities offered by the venture capital firm, ORI is able to use ORIzon to stay abreast of the latest technological Sep20180 ORI Capital Limited developments and market intelligence. This includes access to over two hundred academic journals, updates on the business development of over 10,000 companies and more than 1,000 investment funds in the healthcare sector, and connections with over three hundred key opinion leaders who provide the latest information on technological breakthroughs and opportunities for industry collaboration. The advisors which ORI works with include some of the best and brightest minds in the industry, including the 2009 Nobel Prize Laureate in Physiology or Medicine, Dr Jack Szostak and serial entrepreneur, Dr Norm Weldon, who achieved the Phoenix Lifetime Achievement Award in 2012. In the five years since ORI’s inception, there is no doubt that ORIzon is the firm’s most exciting and significant achievement. However, the work is far from over and ORI will be launching Fund II by the end of 2020, which will again focus on therapeutics, drug delivery and diagnostics companies but this time with a targeted fund size of US$400 million. Always learning and growing its technological capacities, ORI is proving that it has a great future of exponential growth ahead of it, and one that will be contributing to a better way of life. Contact Details: Company: ORI Capital Limited Web Address: www.ori-capital.com

https://www.babblevoice.com/ https://www.grupocetep.com/ https://www.ori-capital.com/ https://www.sonicmedical.co.uk/ https://www.tech4lifeenterprises.com/ https://www.thewellbio.com/